New treatment approaches for airway diseases Ian Pavord
|
|
- Sharleen Chambers
- 7 years ago
- Views:
Transcription
1 New treatment approaches for airway diseases Ian Pavord Professor of Respiratory Medicine University of Oxford Honorary Consultant Physician University of Oxford Hospitals NHS Trust
2 Rosenthal. Thorax 2015;70:
3 Number Asthma treatment costs and hospitalisation rates 100,000 90,000 80,000 70,000 60,000 50,000 40,000 30,000 20,000 10,000 0 Published hospitalisations for asthma, England, 2000/ /08 FCE Admissions Emergency FCE 15+ yrs FCE 0-14yrs 2000/ / / / / / / /08 Source: HESonline Financial year
4 New drug discovery in respiratory diseases Barnes et al. Eur Respir J 2015
5 Sputum eosinophils (%) (mg/ml) Effect of monoclonal antibody to IL-5 (Mepolizumab) on sputum eosinophils and traditional outcomes in asthma Morning PEF (L/min) 20 Placebo group 10mg/kg group 410 Mepolizumab 750 mg Mepolizumab 250 mg Placebo Histamine PC Time relative to dose (days) Time relative to dose (days) Weeks Leckie et al Lancet 2000;356: Flood-Page et al. AJRCCM 2007;176:
6 Getting the basics right
7 Asthma Environmental factors (i.e. allergen) and genetic factors Eosinophilic airway inflammation COPD Environmental factors (i.e. smoking) and genetic factors Neutrophilic airway inflammation Airway hyperresponsiveness Small airway fibrosis, mucus plugging and loss of support Variable airflow limitation Fixed airflow limitation Symptoms Symptoms Exacerbations
8 Cells Eosinophils Neutrophils Macrophages Lymphocytes Epithelial cells Effector mediators LTC/D/E 4 PGD 2 Histamine Cellular markers ECP Neutrophil elastase Cytokines IL-8
9 Change in FEV 1 (l) Sputum eosinophils (%) (% pred) Sputum eosinophil counts in asthma and COPD Asthma Asthma COPD Normal Brightling et al. Lancet 2000;356: ; Green et al. Thorax 2002; 57: Change in FEV <3% 0 Days 14 < >4.5 Eosinophil count >11% 5-11% 3-5% Meijer et al. CEA 2002;32: COPD Brightling et al. Lancet 2000;356:
10 Which patient needs more steroids? No serious attacks Two near fatal attacks
11 FEV 1 (litres) Induced sputum eosinophil count (%) Severe exacerbations (cumulative number) Targeting sputum eosinophilia and severe exacerbations of asthma *p= BTS guidelines (n=37) 6 patients admitted *p= Sputum guidelines (n=37) 1 patient admitted Time (months) Time (months) Green et al. Lancet 2002;360:
12 Exacerbations Eosinophilic inflammation Airway dysfunction + Airway remodelling Cough, breathlessness and wheeze
13 Mepolizumab in severe eosinophilic asthma Parallel group, double blind, placebo controlled trial 61 patients with severe eosinophilic asthma randomised to IV mepolizumab 750 mg monthly or placebo for 12 months Primary outcome: severe exacerbations Haldar et al. NEJM 2009;360:973-84
14 Effect of Mepolizumab (anti-il-5) on airway inflammation and clinical parameters Haldar et al. NEJM 2009;360:973-84
15
16 Is biomarker directed, precision management ready for prime time? The validity and feasibility of assessing airway inflammation is not widely accepted Traditional disease labels and guidelines are deeply embedded Concern about complexity of approach Industry haven t seen an opportunity
17 Simpler biomarkers Type 2 cytokines are released as part of the inflammatory response IL-13 IL-13 IL-5 IL-13/IL-4 Airway lumen Bronchial epithelium Subepi. space Secretion of periostin Periostin is secreted basolaterally and enters the bloodstream Induction of inos, leading to increases in FeNO that can be measured in the breath Eosinophils migrate into the airway lumen and can be measured in sputum Eosinophils can be measured in the blood PERIOSTIN FeNO Bone marrow IL-5 induces eosinophil maturation 1. Sidhu et al. Proc Natl Acad Sci USA. 2010;107: Suresh et al. Am J Respir Cell Mol Biol. 2007;37: Menzies-Gow et al. J Allergy Clin Immunol. 2003;111: Hershey. J Allergy Clin Immunol. 2003;111: BLOOD EOSINOPHILS
18 Change in FEV 1 (%) Biomarkers, risk stratification and identification of steroid responsive disease Risk of attack Response to ICS FE NO (ppb) > < All (n=52) Asthma (n=19) No asthma (n=33) Malinovschi et al. J Allergy Clin Immunol 2013;132:821-7 Smith et al. AJRCCM 2005;172:453-50
19 Mepolizumab: MENSA key results by higher blood eosinophils count (>500/mm 3 ) Reduction of Clinically Significant Exacerbations Across the 3 Treatment Groups at Week 32 Change From Baseline in Pre- and Postbronchodilator FEV 1 Compared to Placebo at Week 32 Supplement to: Ortega et al. N Engl J Med. 2014;371(13):
20 The new pharmacology of eosinophilic airway disease Drug Target Biomarker Clinical effect Symptoms Attacks Mepolizumab (GSK) IL-5 Blood eos + ++ Reslizumab (Teva) IL-5 Blood eos + ++ Benralizumab (AZ) IL-5* Blood eos + ++ Lebrikizumab (Roche) IL-13 Periostin + ++ Tralokinumab (AZ) IL-13 FeNO (?) + ++ Dupilumab (Sanofi) IL-13&4 FeNO (?) QAW039** (Novartis) CRTH2 Blood eos (?) *anti-il-5 receptor ** Orally active
21 Risk assessed using biomarkers of eosinophilic airway inflammation Precision management of airway disease Inflammation predominant disease High dose ICS (oral CS) Biologicals Severe, concordant disease LABA/LAMA/High dose ICS Biologicals Benign disease LABA or LAMA Symptom predominant disease LABA/LAMA Symptom due to airflow limitation Pavord & Agusti. ERJ 2016 in press
22 Inhaled steroids and the risk of pneumonia in patients with COPD Suissa et al. Thorax 2013;68:
23 The effect of addition of Fluticasone Furoate (FF) to Vilanterol (VI) Aim: to determine if the combination of FF and VI is more protective than VI alone against COPD exacerbations Two studies of identical design Baseline blood eosinophil count available N=3255 Diagnosis of COPD (ATS/ERS definition) Aged 40 years 4-week FP/Sal BD run-in period 1 COPD exacerbation in the year before screening Randomise FF/VI 46/22 mcg (n=820) FF/VI 92/22 mcg (n=806) FF/VI 184/22 mcg (n=811) VI 22 mcg (n=818) For 52 weeks Once daily (in the morning) using a dry powder inhaler Dransfield et al. Lancet Respir Med. 2013;1:
24 Annual Exacerbation Rate The effect of addition of Fluticasone Furoate to Vilanterol by blood eosinophils in COPD 1.7 FF/VI, all doses Vilanterol 25mcg 42% diff p= % diff p= % diff p= % diff p= n=799 n=299 n=907 n=302 n=395 n=113 n=281 n=85 0 to <2% 2% to <4% 4% to <6% 6% or more Pascoe et al. Lancet Resp Med 2015 Blood eosinophil count (%)
25 Risk assessed using biomarkers of eosinophilic airway inflammation Where are the gaps? Inflammation predominant disease High dose ICS (oral CS) Biologicals Severe, concordant disease LABA/LAMA/High dose ICS Biologicals Benign disease LABA or LAMA Symptom predominant disease LABA/LAMA Symptom due to airflow limitation 1. Symptoms not due to airflow limitation 2. Attacks (and symptoms) not due to eosinophilic airway inflammation Pavord & Agusti. ERJ 2016
26 Capsaicin C2 (mcmol) Coughs in 24 hours Cough reflex hypersensitivity as a treatable trait female male 1000 males on ACEi Normal Yousaf et al. ERJ 2013 Unexplained CVA/EB COPD Bronchiectasis Asthma ILD
27 Cough reflex hypersensitivity and P2X3 antagonist Abdulqawi et al. Lancet 2014
28 Is neutrophilic airway inflammation a target? Neutrophil Elastase ng/ml IL-8 ng/ml COPD Asthma Albert et al. NEJM 2011;365: Bronchiectasis Wong et al. Lancet 2012;380: *# Clarithromycin Placebo Baseline After treatment Treatment withdrawn # #P<0.05 Clarithromycin Placebo Baseline After treatment Treatment withdrawn Simpson et al. AJRCCM 2008;177:
29 CXCR2 antagonist as a means of investigating neutrophilic airway disease Blood neutrophils Sputum neutrophils n=12 n= vs 2.25 mild exacerbations/patient (p=0.15) 0.42 difference in change in ACQ (p=0.053) Nair et al. Clin Exp Allergy 2012;42:
30 Are there two types of neutrophilic airway disease? Macrolides Han et al. Am J Respir Crit Care Med 2014;189: CXCR2 antagonist Rennard et al. Am J Respir Crit Care Med 2015;191:
31 Conclusions Progress has required a rethink of basic concepts Biomarkers of eosinophilic airway inflammation identify risk and likely treatment responsiveness Clinical approach needs to move away from categorisation to analysis and identification of this and other treatable traits Industry is engaged
32 Acknowledgements Mona Bafadhel Luzheng Xue Bart Hilvering Rahul Shrimanker Kirsty Hambleton Graham Ogg Paul Klenerman Samantha Thulborn Tim Powell Jenny Kane Katie Borg Clare Connelly Our patients
Asthma (With a little SCID to start) Disclosures Outline Starting with the Immune System The Innate Immune System The Adaptive Immune System
1 2 3 4 5 6 7 8 9 Asthma (With a little SCID to start) Lauren Smith, MD CHKD Pediatric Allergy/Immunology Disclosures None Will be discussing some medications that are not yet FDA approved Outline SCID
More information9/16/2014. Anti-Immunoglobulin E (IgE) Omalizumab (Xolair ) Dosing Guidance
Disclosure Statement of Financial Interest New Therapies for Asthma Including Omalizumab and Anti-Cytokine Therapies Marsha Dangler, PharmD, BCACP Clinical Pharmacy Specialist James H. Quillen VA Medical
More informationHow to use FENO-guided asthma control in routine clinical practice
How to use FENO-guided asthma control in routine clinical practice Asthma is a chronic inflammatory disease of the airways. This has implications for the diagnosis, management and potential prevention
More informationBackground information
Background information Asthma Asthma is a complex disease affecting the lungs that can be managed but cannot be cured. 1 Asthma can be controlled well in most people most of the time, although some people
More informationPrevention of Acute COPD exacerbations
December 3, 2015 Prevention of Acute COPD exacerbations George Pyrgos MD 1 Disclosures No funding received for this presentation I have previously conducted clinical trials with Boehringer Ingelheim. Principal
More informationTopic: New Treatment = Better Outcome?
Session on COPD: Novel Concepts and Promising New Drugs Topic: New Treatment = Better Outcome? Through a CME Grant sponsored by New Treatment = Better Outcome? Tim S. Trinidad, MD Disclosure Present: COPD
More informationBronchodilators in COPD
TSANZSRS Gold Coast 2015 Can average outcomes in COPD clinical trials guide treatment strategies? Long live the FEV1? Christine McDonald Dept of Respiratory and Sleep Medicine Austin Health Institute for
More informationOn completion of this chapter you should be able to: discuss the stepwise approach to the pharmacological management of asthma in children
7 Asthma Asthma is a common disease in children and its incidence has been increasing in recent years. Between 10-15% of children have been diagnosed with asthma. It is therefore a condition that pharmacists
More informationSevere asthma Definition, epidemiology and risk factors. Mina Gaga Athens Chest Hospital
Severe asthma Definition, epidemiology and risk factors Mina Gaga Athens Chest Hospital Difficult asthma Defined as asthma, poorly controlled in terms of chronic symptoms, with episodic exacerbations,
More informationExploratory data: COPD and blood eosinophils. David Price: 9.23-9.35am
Exploratory data: COPD and blood eosinophils David Price: 9.23-9.35am Blood Eosinophilia in COPD The reliability and utility of blood eosinophils as a marker of disease burden, healthcare resource utilisation
More informationunderstanding the professional guidelines
SEVERE ASTHMA understanding the professional guidelines This guide includes information on what the European Respiratory Society (ERS) and the American Thoracic Society (ATS) have said about severe asthma.
More informationThe Problem with Asthma. Ruth McArthur, Practice Nurse/Trainer
The Problem with Asthma Ruth McArthur, Practice Nurse/Trainer Getting the diagnosis right! Asthma or COPD? History taking is key Both are inflammatory conditions with different mechanisms & mediators Diagnostic
More informationPharmacology of the Respiratory Tract: COPD and Steroids
Pharmacology of the Respiratory Tract: COPD and Steroids Dr. Tillie-Louise Hackett Department of Anesthesiology, Pharmacology and Therapeutics University of British Columbia Associate Head, Centre of Heart
More informationMepolizumab Treatment in Patients with Severe Eosinophilic Asthma
The new england journal of medicine original article Mepolizumab Treatment in Patients with Severe Eosinophilic Asthma Hector G. Ortega, M.D., Sc.D., Mark C. Liu, M.D., Ian D. Pavord, D.M., Guy G. Brusselle,
More informationStanley J. Szefler, MD National Jewish Medical and Research Center
New Asthma Guidelines: Special Attention to Infant Wheezers Stanley J. Szefler, MD Helen Wohlberg & Herman Lambert Chair in Pharmacokinetics, & Professor of Pediatrics and Pharmacology, University of Colorado
More informationIdiopathic Pulmonary Fibrosis (IPF) Research
Idiopathic Pulmonary Fibrosis (IPF): Why Early Referral is Critical Even if Your Patient is Not Eligible for a Clinical Trial Idiopathic Pulmonary Fibrosis (IPF) Research Management of IPF requires a confident
More informationProf. Florian Gantner. Vice President Respiratory Diseases Research Boehringer Ingelheim
Prof. Florian Gantner Vice President Respiratory Diseases Research Boehringer Ingelheim Research and Development in Practice: COPD Chronic Obstructive Pulmonary Disease (COPD) Facts Main cause of COPD
More informationCompare the physiologic responses of the respiratory system to emphysema, chronic bronchitis, and asthma
Chapter 31 Drugs Used to Treat Lower Respiratory Disease Learning Objectives Describe the physiology of respirations Compare the physiologic responses of the respiratory system to emphysema, chronic bronchitis,
More informationMonoclonal Antibodies in Asthma Therapy. Yehia El-Gamal MD, PhD
Monoclonal Antibodies in Asthma Therapy Yehia El-Gamal MD, PhD Conflict of Interest Nothing to disclose Objectives Following this presentation, the audience should be able to: Recognize some important
More informationSponsor Novartis Pharmaceuticals
Clinical Trial Results Database Page 1 Sponsor Novartis Pharmaceuticals Generic Drug Name Indacaterol Therapeutic Area of Trial Chronic Obstructive Pulmonary Disease (COPD) Indication studied: COPD Study
More informationNIOX VERO. For assessment and management of airway inflammation
NIOX VERO For assessment and management of airway inflammation NIOX VERO NIOX VERO is a point-of-care device for assessing airway inflammation in patients with respiratory problems such as asthma. NIOX
More informationPipeline: Respiratory, Inflammation & Autoimmunity (RIA) Inhaled therapeutic leadership; spearheading immunology biologics
Pipeline: Respiratory, Inflammation & Autoimmunity (RIA) Inhaled therapeutic leadership; spearheading immunology biologics Bing Yao, Head of MedImmune Respiratory, Inflammation & Autoimmunity imed Respiratory:
More informationClassifying Asthma Severity and Initiating Treatment in Children 0 4 Years of Age
Classifying Asthma Severity and Initiating Treatment in Children 0 4 Years of Age Components of Severity Symptoms Intermittent 2 days/week Classification of Asthma Severity (0 4 years of age) Persistent
More informationClinical Research Pediatric Pulmonary Division
Clinical Research Pediatric Pulmonary Division Hengameh H. Raissy, PharmD Research Associate Professor, Pediatric Pulmonary UNM HSC Director of Clinical Trials Presented at Envision NM Asthma / Pulmonary
More informationPLAN OF ACTION FOR. Physician Name Signature License Date
PLAN OF ACTION FOR Patient s copy (patient s name) I Feel Well Lignes I feel short directrices of breath: I cough up sputum daily. No Yes, colour: I cough regularly. No Yes I Feel Worse I have changes
More informationRES/006/APR16/AR. Speaker : Dr. Pither Sandy Tulak SpP
RES/006/APR16/AR Speaker : Dr. Pither Sandy Tulak SpP Definition of Asthma (GINA 2015) Asthma is a common and potentially serious chronic disease that imposes a substantial burden on patients, their families
More informationAsthma diagnosis and treatment: Filling in the information gaps
Asthma: Current status and future directions Asthma diagnosis and treatment: Filling in the information gaps William W. Busse, MD Madison, Wis Current approaches to the diagnosis and management of asthma
More informationAsthma COPD and Asthma - COPD Overlap Syndrome (ACOS)
Diagnosis of Diseases of Chronic Airflow Limitation: Asthma COPD and Asthma - COPD Overlap Syndrome (ACOS) Based on the Global Strategy for Asthma Management and Prevention and the Global Strategy for
More informationCOPD and Asthma Differential Diagnosis
COPD and Asthma Differential Diagnosis Chronic Obstructive Pulmonary Disease (COPD) is the third leading cause of death in America. Learning Objectives Use tools to effectively diagnose chronic obstructive
More informationAsthma COPD and Asthma - COPD Overlap Syndrome (ACOS)
Diagnosis of Diseases of Chronic Airflow Limitation: Asthma COPD and Asthma - COPD Overlap Syndrome (ACOS) Based on the Global Strategy for Asthma Management and Prevention and the Global Strategy for
More informationCOPD Prescribing Guidelines
South Staffordshire Area Prescribing Group COPD Prescribing Guidelines Inhaler choices in this guideline are different from previous versions produced by the APG. It is not expected patients controlled
More informationGuideline on the clinical investigation of medicinal products for the treatment of asthma
22 October 2015 CHMP/EWP/2922/01 Rev.1 Committee for Medicinal Products for Human Use (CHMP) Guideline on the clinical investigation of medicinal products for the treatment of Draft Agreed by Respiratory
More informationSevere asthma: Advances in current management and future therapy
Asthma: Current status and future directions Severe asthma: Advances in current management and future therapy Peter J. Barnes, FMedSci, FRS London, United Kingdom Effective treatment of severe asthma is
More informationRSPT 2317 Non-steroidal anti-asthma agents
RSPT 2317 Non-steroidal Anti-asthma Agents Mechanisms of Inflammation in Asthma Mechanisms of Inflammation in Asthma Asthma is a chronic inflammatory disorder of the airways It is divided into extrinsic
More informationObjectives. Asthma Management
Objectives Asthma Management BREATHE Conference Allergy and Asthma Specialists PC Christine Malloy MD March 22, 2013 Review the role of inflammation in asthma Discuss the components of the EPR-3 management
More informationManagement of exacerbations in chronic obstructive pulmonary disease in Primary Care
Management of exacerbations in chronic obstructive pulmonary disease in Primary Care Acute exacerbations of chronic obstructive pulmonary disease (COPD) are associated with significant morbidity and mortality.
More informationPre-Operative Services Teaching Rounds 2 Jan 2011
Pre-Operative Services Teaching Rounds 2 Jan 2011 Deborah Richman MBChB FFA(SA) Director Pre-Operative Services Department of Anesthesia Stony Brook University Medical Center, NY drichman@notes.cc.sunysb.edu
More informationImmunology and immunotherapy in allergic disease
Immunology and immunotherapy in allergic disease Jing Shen, MD Faculty Advisor: Matthew Ryan, MD The University of Texas Medical Branch Department of Otolaryngology Grand Rounds Presentation February 2005
More informationWheezing in Children. Prof RJ Green Department of Paediatrics
Wheezing in Children Prof RJ Green Department of Paediatrics Adventitious Airway Sounds Snoring Stridor Wheezing Crepitations Airway Diameter Cause of Wheezing Not from obstruction of small airways Surface
More informationAsthma in Infancy, Childhood and Adolescence. Presented by Frederick Lloyd, MD Palo Alto Medical Foundation Palo Alto, California
Asthma in Infancy, Childhood and Adolescence Presented by Frederick Lloyd, MD Palo Alto Medical Foundation Palo Alto, California Major Health Problem in Childhood Afflicts 2.7 million children in the USA
More informationCOPD PROTOCOL CELLO. Leiden
COPD PROTOCOL CELLO Leiden May 2011 1 Introduction This protocol includes an explanation of the clinical picture, diagnosis, objectives and medication of COPD. The Cello way of working can be viewed on
More informationBritish Guideline on the Management of Asthma
101 British Guideline on the Management of Asthma A national clinical guideline May 2008 revised May 2011 KEY TO EVIDENCE STATEMENTS AND GRADES OF RECOMMENDATIONS LEVELS OF EVIDENCE 1 ++ High quality meta-analyses,
More informationESCMID Online Lecture Library. by author
Do statins improve outcomes of patients with sepsis and pneumonia? Jordi Carratalà Department of Infectious Diseases Statins for sepsis & community-acquired pneumonia Sepsis and CAP are major healthcare
More informationREAD THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE PATIENT MEDICATION INFORMATION. [new-ka la]
READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE PATIENT MEDICATION INFORMATION Pr NUCALA [new-ka la] mepolizumab lyophilized powder for subcutaneous injection Read this carefully before you start
More informationBreaking News in Malattie dell Apparato Respiratorio
COMPROMISSIONE FUNZIONALE RESPIRATORIA E/O COMORBIDITÀ RESPIRATORIE IN PAZIENTI AFFETTI DALLE PRINCIPALI PATOLOGIE CRONICHE Modena 1-3 Ottobre 2015 Breaking News in Malattie dell Apparato Respiratorio
More informationGuidance to support the stepwise review of combination inhaled corticosteroid therapy for adults ( 18yrs) in asthma
Guidance to support the stepwise review of combination inhaled corticosteroid therapy for adults ( 18yrs) in asthma Important Complete asthma control needs to be achieved for at least 12 weeks before attempting
More information5. Treatment of Asthma in Children
Treatment of sthma in hildren 5. Treatment of sthma in hildren 5.1 Maintenance Treatment 5.1.1 rugs Inhaled Glucocorticoids. Persistent wheezing in children under the age of three can be controlled with
More informationBritish Guideline on the Management of Asthma
101 British Guideline on the Management of Asthma A national clinical guideline May 2008 Revised January 2012 KEY TO EVIDENCE STATEMENTS AND GRADES OF RECOMMENDATIONS LEVELS OF EVIDENCE 1 ++ High quality
More informationBefore prescribing for COPD management, the patient should have had appropriate assessment, including spirometry, as per NICE guidelines.
Formulary Guidance for Management of COPD patients Before prescribing for COPD management, the patient should have had appropriate assessment, including spirometry, as per NICE guidelines. For inhaler
More informationFrequent co-morbid conditions with asthma. Nelson Rosário MD, PhD, FAAAAI, FACAAI
Frequent co-morbid conditions with asthma Nelson Rosário MD, PhD, FAAAAI, FACAAI Comorbidities in childhood asthma Knowledge is sparse. Further studies are needed: to identify the prevalence the effects
More informationEffects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response
Early reports Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response Margaret J Leckie, Anneke ten Brinke, Jamey Khan, Zuzana
More informationObjectives COPD. Chronic Obstructive Pulmonary Disease (COPD) 4/19/2011
Objectives Discuss assessment findings and treatment for: Chronic Obstructive Pulmonary Disease Bronchitis Emphysema Asthma Anaphylaxis Other respiratory issues Provide some definitions Chronic Obstructive
More informationPosition Statement from the Irish Thoracic Society on the treatment of Idiopathic Pulmonary Fibrosis
BACKGROUND Position Statement from the Irish Thoracic Society on the treatment of Idiopathic Pulmonary Fibrosis Idiopathic Pulmonary Fibrosis (IPF) is a rare, chronic and fatal disease characterised by
More informationASTHMA IN INFANTS AND YOUNG CHILDREN
ASTHMA IN INFANTS AND YOUNG CHILDREN What is Asthma? Asthma is a chronic inflammatory disease of the airways. Symptoms of asthma are variable. That means that they can be mild to severe, intermittent to
More informationStephen R. Veach, M.D.
Stephen R. Veach, M.D. Memorial Sloan-Kettering Cancer Center International Oncology Programs 160 E. 53 rd Street New York, NY 10022 212-610 610-08780878 - tel 212-308 308-7063 - fax veachs@mskcc.org SCREENING
More informationThe Link Between Viruses and Asthma Catherine Kier, M.D.
The Link Between Viruses and Asthma Catherine Kier, M.D. Professor of Clinical Pediatrics Division Chief, Pediatric Pulmonary Director, Cystic Fibrosis Center No disclosures Objectives: At the end of this
More informationThis clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.
abcd Clinical Study for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis which is part of the clinical
More informationHypersensitivity. TYPE I Hypersensitivity Classic allergy. Allergens. Characteristics of allergens. Allergens. Mediated by IgE attached to Mast cells.
Gel and Coombs classification of hypersensitivities. Hypersensitivity Robert Beatty Type I Type II Type III Type IV MCB150 IgE Mediated IgG/IgM Mediated IgG Mediated T cell Classic Allergy rbc lysis Immune
More informationAsthma is a chronic inflammatory condition of the
Evaluation of Salmeterol or Montelukast as Second-Line Therapy for Asthma Not Controlled With Inhaled Corticosteroids* Andrew M. Wilson, MD; Owen J. Dempsey, MD; Erika J. Sims, BSc; and Brian J. Lipworth,
More informationTests. Pulmonary Functions
Pulmonary Functions Tests Static lung functions volumes Dynamic lung functions volume and velocity Dynamic Tests Velocity dependent on Airway resistance Resistance of lung tissue to change in shape Dynamic
More informationFrom the Text. Clinical Indications. Clinical Indications. RSPT 2217 Non-steroidal Anti-asthma Agents. RSPT 2317 Non-steroidal Antiasthma Agents
From the Text RSPT 2317 Non-steroidal Antiasthma Agents Gardenhire Chapter 12 Key Terms and Definitions Page 226 Nonsteroidal Antiasthma Meds Table 12-1; page 228 Comparative Features of Antileukotriene
More informationNote for guidance on clinical investigation of medicinal products for treatment of asthma
1 2 3 27 June 2013 CHMP/EWP/2922/01 Rev.1 Committee for Medicinal Products for Human Use (CHMP) 4 5 6 Note for guidance on clinical investigation of medicinal products for treatment of asthma Draft Draft
More informationChapter 43: The Immune System
Name Period Our students consider this chapter to be a particularly challenging and important one. Expect to work your way slowly through the first three concepts. Take particular care with Concepts 43.2
More informationOriginal article: Sumito Inoue*, Yoko Shibata, Noriaki Takabatake, Akira Igarashi, Shuichi Abe, Isao Kubota
Original article: INFLUENCE OF CORTICOSTEROID THERAPY ON THE SERUM ANTIBODY RESPONSE TO INFLUENZA VACCINE IN ELDERLY PATIENTS WITH CHRONIC PULMONARY DISEASES Sumito Inoue*, Yoko Shibata, Noriaki Takabatake,
More informationSide effect of drugs, such as amphetamines, tranquilizers, bulk-type laxatives containing psyllium and certain antibiotics
Eosinophils Eosinophils are a type of white blood cell. A normal eosinophil count is less than 350 cells per microliter of blood. The exact role of eosinophils in your body is unclear, but eosinophils
More information4-Deveci F, Akbulut HH, Çelik I, Muz MH Ilhan F. Lymphocyte Subpopulations in Pulmonary Tuberculosis Patients, Mediators Inflamm., 2006;(2);89070.
CURRICULUM VITAE Personal Details Surname: Muz Frst Name: Mehmet Hamdi Academic title/position: Prof. Dr.- President of Chest Disease Departmant Key Qualifcations: Research Interest: Lung Cancers Đnternational
More informationadrenoceptor agonists and the Olympic Games in Turin
Beta 2 adrenoceptor agonists and the Olympic Games in Turin 1. INTRODUCTION Article 4 of the World Anti-Doping Code refers to the Prohibited List as the international standard. This List, which came into
More informationDisclosures. Consultant and Speaker for Biogen Idec, TEVA Neuroscience, EMD Serrono, Mallinckrodt, Novartis, Genzyme, Accorda Therapeutics
Mitzi Joi Williams, MD Neurologist MS Center of Atlanta, Atlanta, GA Disclosures Consultant and Speaker for Biogen Idec, TEVA Neuroscience, EMD Serrono, Mallinckrodt, Novartis, Genzyme, Accorda Therapeutics
More informationPulmonary Disorders. Chronic Obstructive Pulmonary Disease (COPD) Chronic Obstructive Pulmonary Disease (COPD)
RCS 6080 Medical and Psychosocial Aspects of Rehabilitation Counseling Pulmonary Disorders Chronic Obstructive Pulmonary Disease (COPD) Characterized by decreased expiratory airflow Reduction in expiratory
More informationse.bonini@gmail.com Modena March 3, 2009
A novel molecular marker of severe asthma Sergio Bonini Professor of Medicine, Second University of Naples INMM-CNR, ARTOV, Rome se.bonini@gmail.com i@ il Modena March 3, 2009 Circulating nerve growth
More informationSummary of the risk management plan (RMP) for Orkambi (lumacaftor and ivacaftor)
EMA/662624/2015 Summary of the risk management plan (RMP) for Orkambi (lumacaftor and ivacaftor) This is a summary of the risk management plan (RMP) for Orkambi, which details the measures to be taken
More informationLothian Guideline for Domiciliary Oxygen Therapy Service for COPD
Lothian Guideline for Domiciliary Oxygen Therapy Service for COPD This document describes the standard for clinical assessment, prescription, optimal management and follow-up of patients receiving domiciliary
More informationAn Overview of Asthma - Diagnosis and Treatment
An Overview of Asthma - Diagnosis and Treatment Asthma is a common chronic disorder of the airways that is complex and characterized by variable and recurring symptoms, airflow obstruction, bronchial hyperresponsiveness,
More informationAsthma POEMs. Patient Orientated Evidence that Matters
ASTHMA POEMs Asthma POEMs Patient Orientated Evidence that Matters Developed by the Best Practice Advocacy Centre Level 8, 10 George Street PO Box 6032 Dunedin Phone 03 4775418 Fax 03 4772622 Acknowledgement
More informationEffect of montelukast added to inhaled corticosteroids on fractional exhaled nitric oxide in asthmatic children
Eur Respir J 2002; 20: 630 634 DOI: 10.1183/09031936.02.01512002 Printed in UK all rights reserved Copyright #ERS Journals Ltd 2002 European Respiratory Journal ISSN 0903-1936 Effect of montelukast added
More informationInfluenza (Flu) Influenza is a viral infection that may affect both the upper and lower respiratory tracts. There are three types of flu virus:
Respiratory Disorders Bio 375 Pathophysiology General Manifestations of Respiratory Disease Sneezing is a reflex response to irritation in the upper respiratory tract and is associated with inflammation
More informationMonoclonal anti-interleukin-5 treatment suppresses eosinophil but not T-cell functions
Eur Respir J 3; : 799 3 DOI:.3/9393.3.73 Printed in UK all rights reserved Copyright #ERS Journals Ltd 3 European Respiratory Journal ISSN 93-93 Monoclonal anti-interleukin- treatment suppresses eosinophil
More informationCOPD is the fourth most common cause of death. Gender Bias in the Diagnosis of COPD*
Gender Bias in the Diagnosis of COPD* Kenneth R. Chapman, MD, FCCP; Donald P. Tashkin, MD, FCCP; and David J. Pye, PhD Background: COPD is thought to be more prevalent among men than women, a finding usually
More informationAsthma. SS Visser, Lung Unit, UP
Asthma SS Visser, Lung Unit, UP Contents Definition Disease Pattern Prevalence Mortality Etiology Pathogenesis Triggers of acute attacks Contents Pathophysiology Manifestations of Resp failure Diagnosis:
More informationJ.P. Morgan Cazenove Therapeutic Seminar
Jannan, MS J.P. Morgan Cazenove Therapeutic Seminar David Meeker - CEO, Genzyme June 25, 2012 Forward Looking Statements This presentation contains forward-looking statements as defined in the Private
More informationPulsating Aerosol. The New Wave in SINUSitis Therapy. For the precise, effective and gentle treatment of sinusitis
The New Wave in SINUSitis Therapy Pulsating Aerosol For the precise, effective and gentle treatment of sinusitis PARI SINUS Inhalation treatment for acute and chronic diseases of the upper airways www.parimedical.co.uk
More informationCo-morbiditeit associeert met respiratoire aandoeningen louter omwille van de leeftijd. COPD patiënten hebben veel meer kans op longkanker dan rokers
Academisch centrum huisartsgeneeskunde Pneumologie Juni 2012 Prof W Janssens Co-morbiditeit associeert met respiratoire aandoeningen louter omwille van de leeftijd. COPD patiënten hebben veel meer kans
More informationCorporate Medical Policy Genetic Testing for Alpha-1 Antitrypsin Deficiency
Corporate Medical Policy Genetic Testing for Alpha-1 Antitrypsin Deficiency File Name: Origination: Last CAP Review: Next CAP Review: Last Review: genetic_testing_for_alpha_1_antitrypsin_deficiency 5/2012
More informationCOPD MANAGEMENT PROTOCOL STANFORD COORDINATED CARE
I. PURPOSE To establish guidelines f the collabative management of patients with a diagnosis of chronic obstructive pulmonary disease (COPD) who are not adequately controlled and to define the roles and
More information30 DAY COPD READMISSIONS AND PULMONARY REHAB
30 DAY COPD READMISSIONS AND PULMONARY REHAB Trina M. Limberg, Bs, RRT, FAARC, MAACVPR Director, Preventative Pulmonary and Rehabilitation Services UC San Diego Health System OVERVIEW The Impact of COPD
More informationPost-market review of COPD medicines. Joint submission from Lung Foundation Australia (LFA) and Thoracic Society of Australia and New Zealand (TSANZ)
Post-market review of COPD medicines Joint submission from Lung Foundation Australia (LFA) and Thoracic Society of Australia and New Zealand (TSANZ) EXECUTIVE SUMMARY With the addition of new medicines
More informationUse of Azithromycin in Children with Non-Cystic Fibrosis Bronchiectasis or Chronic Suppurative Lung Disease
Use of Azithromycin in Children with Non-Cystic Fibrosis Bronchiectasis or Chronic Suppurative Lung Document ID CHQ-GDL-01061 Version no. 2.0 Approval date 28/08/2015 Executive sponsor Executive Director
More informationDisease/Illness GUIDE TO ASBESTOS LUNG CANCER. What Is Asbestos Lung Cancer? www.simpsonmillar.co.uk Telephone 0844 858 3200
GUIDE TO ASBESTOS LUNG CANCER What Is Asbestos Lung Cancer? Like tobacco smoking, exposure to asbestos can result in the development of lung cancer. Similarly, the risk of developing asbestos induced lung
More informationHodgkin Lymphoma Disease Specific Biology and Treatment Options. John Kuruvilla
Hodgkin Lymphoma Disease Specific Biology and Treatment Options John Kuruvilla My Disclaimer This is where I work Objectives Pathobiology what makes HL different Diagnosis Staging Treatment Philosophy
More informationJ of Evolution of Med and Dent Sci/ eissn- 2278-4802, pissn- 2278-4748/ Vol. 3/ Issue 65/Nov 27, 2014 Page 13575
EFFECT OF BREATHING EXERCISES ON BIOPHYSIOLOGICAL PARAMETERS AND QUALITY OF LIFE OF PATIENTS WITH COPD AT A TERTIARY CARE CENTRE Sudin Koshy 1, Rugma Pillai S 2 HOW TO CITE THIS ARTICLE: Sudin Koshy, Rugma
More informationMeasuring fractional exhaled nitric oxide concentration in asthma: NIOX MINO, NIOX VERO and NObreath
Measuring fractional exhaled nitric oxide concentration in asthma: NIOX MINO, NIOX VERO and NObreath Issued: April 2014 www.nice.org.uk/dg12 NICE has accredited the process used by the Centre for Health
More informationRESPIRATORY VENTILATION Page 1
Page 1 VENTILATION PARAMETERS A. Lung Volumes 1. Basic volumes: elements a. Tidal Volume (V T, TV): volume of gas exchanged each breath; can change as ventilation pattern changes b. Inspiratory Reserve
More informationUnderstanding Asthma Patients in the Dental Office
Understanding Asthma Patients in the Dental Office Barbara Fried, RDH, MBA Continuing Education Units: 1 hour Online Course: www.dentalcare.com/en-us/dental-education/continuing-education/ce408/ce408.aspx
More informationDrug therapy SHORT-ACTING BETA AGONISTS SHORT-ACTING ANTICHOLINERGICS LONG-ACTING BETA AGONISTS LONG-ACTING ANTICHOLINERGICS
Drug therapy 6 6.1 What is the role of bronchodilators in COPD? 52 SHORT-ACTING BETA AGONISTS 6.2 How do short-acting beta agonists work? 52 6.3 What are the indications for their use? 52 6.4 What is the
More informationThese factors increase your chance of developing emphysema. Tell your doctor if you have any of these risk factors:
Emphysema Pronounced: em-fiss-see-mah by Debra Wood, RN En Español (Spanish Version) Definition Emphysema is a chronic obstructive disease of the lungs. The lungs contain millions of tiny air sacs called
More informationCOPD It Can Take Your Breath Away www.patientedu.org
written by Harvard Medical School COPD It Can Take Your Breath Away www.patientedu.org What Is COPD? COPD stands for chronic obstructive pulmonary disease. There are 2 major diseases included in COPD:
More informationGuideline on clinical investigation of medicinal products in the treatment of chronic obstructive pulmonary disease (COPD)
21 June 2012 EMA/CHMP/483572/2012 -corr 1 Respiratory Drafting Group Guideline on clinical investigation of medicinal products in the treatment of chronic obstructive pulmonary disease (COPD) Draft Agreed
More informationGCE AS/A level 1661/01A APPLIED SCIENCE UNIT 1. Pre-release Article for Examination in January 2010 JD*(A09-1661-01A)
GCE AS/A level 1661/01A APPLIED SCIENCE UNIT 1 Pre-release Article for Examination in January 2010 JD*(A09-1661-01A) 2 BLANK PAGE 3 Information for Teachers The attached article on asthma is based on some
More informationManagement of Asthma
Federal Bureau of Prisons Clinical Practice Guidelines May 2013 Clinical guidelines are made available to the public for informational purposes only. The Federal Bureau of Prisons (BOP) does not warrant
More informationWhat You Should Know About ASTHMA
What You Should Know About ASTHMA 200 Hospital Drive Galax, VA 24333 (276) 236-8181 www.tcrh.org WHAT IS ASTHMA? It s a lung condition that makes breathing difficult. The cause of asthma is not known.
More information